Science
Arndt Vogel: A Phase III Trial on [177Lu] Lu-edotreotide Versus Everolimus
Arndt Vogel/aasld.org

Arndt Vogel: A Phase III Trial on [177Lu] Lu-edotreotide Versus Everolimus

Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X:

“[¹⁷⁷Lu]Lu-edotreotide versus everolimus for gastroenteropancreaticNET (COMPETE)

  • ORR: 22 vs 4%
  • mPFS: 23.9 vs 14.1 mo
  • mOS: 63 vs 58 mo
  • Support PRRT as effective 2nd line treatment”
Title: [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

Authors: Thomas Walter, Henning Jann, Catherine Ansquer, Emmanuel Deshayes, Rocio Garcia-Carbonero, Alexandre Teulé, Richard P Baum, Hein J Verberne, Jarosław B Ćwikła, Rajaventhan Srirajaskanthan, Louis de Mestier, Chiara M Grana, Andreas Buck, Dieter Hörsch, Marianne Pavel, Lawrence O Dierickx, Michael Michael, Jonathan Strosberg, Attila Kollár, Paula Jimenez-Fonseca, Anja Rinke, Maribel del Olmo-García, Anthime Flaus, Jorge Hernando, Andreas Kluge, Monika Breuninger, Dipl Statz, Serhii Melnyk, Konstantin Zhernosekov, Jaume Capdevila.

Read the article

Arndt Vogel

Other articles about GI Oncology on OncoDaily.

Alexandre Teulé Andreas Buck Andreas Kluge Anja Rinke Anthime Flaus Arndt Vogel Attila Kollár cancer Catherine Ansquer Chiara M Grana Dieter Hörsch Dipl Statz Emmanuel Deshayes GI oncology Hein J Verberne Henning Jann Jarosław B Ćwikła Jaume Capdevila Jonathan Strosberg Jorge Hernando Konstantin Zhernosekov Lawrence O Dierickx Louis de Mestier Marianne Pavel Maribel del Olmo-García Michael Michael Monika Breuninger OncoDaily Oncology Paula Jimenez-Fonseca Rajaventhan Srirajaskanthan Richard P. Baum Rocio Garcia-Carbonero Serhii Melnyk Thomas Walter